Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cell. 2012 Mar 30;149(1):22-35. doi: 10.1016/j.cell.2012.03.003.

MYC on the path to cancer.

Author information

  • 1Division of Hematology-Oncology, Department of Medicine, Abramson Cancer Center, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. dangvchi@upenn.edu

Abstract

The MYC oncogene contributes to the genesis of many human cancers. Recent insights into its expression and function have led to therapeutic opportunities. MYC's activation by bromodomain proteins could be inhibited by drug-like molecules, resulting in tumor inhibition in vivo. Tumor growth can also be curbed by pharmacologically uncoupling bioenergetic pathways involving glucose or glutamine metabolism from Myc-induced cellular biomass accumulation. Other approaches to halt Myc on the path to cancer involve targeting Myc-Max dimerization or Myc-induced microRNA expression. Here the richness of our understanding of MYC is reviewed, highlighting new biological insights and opportunities for cancer therapies.

Copyright © 2012 Elsevier Inc. All rights reserved.

PMID:
22464321
[PubMed - indexed for MEDLINE]
PMCID:
PMC3345192
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk